GSK To Pay $$2.2 Billion To Settle Majority Of Zantac Cases In United States
LONDON — GSK PLC announced Oct. 9 that it has reached settlement agreements to end approximately 80,000 Zantac (ranitidine) state court product liability cases pending against the pharmaceutical company in the...To view the full article, register now.
Already a subscriber? Click here to view full article